To validate these results, we used the PPMI data to determine if the levels of the PWAS-significant proteins were significantly different between controls, sporadic, PD cases, or individuals with autosomal dominant PD mutations (LRRK2 + , GBA + , SNCA + ; prodromal cases). This evidence concerns the gene LRRK2 and Parkinson disease.